SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as the community speculates on the potential passage of the Clarity Act, with many hoping it will establish the token as a digital commodity and clarify its long-term utility for collateralized payments. While long-term holders debate whether recent price fluctuations represent institutional accumulation or ongoing market manipulation, community sentiment remains sharply divided between those calling for patience in anticipation of institutional adoption and those frustrated by the prolonged downward trend and perceived lack of clear communication from project leadership.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is experiencing extreme volatility as investors react to a sharp pullback in gold prices, driven by profit-taking and margin adjustments following a historic price rally. The community is actively debating whether this decline represents a major trend reversal or a healthy consolidation, with many investors closely watching support levels while speculating on the impact of ongoing geopolitical tensions in the Middle East.

Cheniere Energy, Inc. engages in liquefied natural gas (LNG) related businesses. It owns and operates LNG terminals, develops, constructs, and operates liquefaction projects near Corpus Christi, Texas, and at the Sabine Pass LNG terminal. The company was founded by Charif Souki in 1996 and is headquartered in Houston, TX.

Cheniere Energy Inc.

Cheniere Energy is attracting significant attention as investors speculate on its potential inclusion in the S&P 500, a move fueled by its strong market position and role in the critical U.S. LNG export sector. Meanwhile, the community is actively debating the stock's growth trajectory and its value proposition compared to emerging competitors like Venture Global, with sentiment heavily influenced by geopolitical energy shifts and robust institutional interest.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. is drawing significant attention as investors react to the company's strategic positioning within the North American uranium and rare-earth supply chains, further buoyed by a fresh buy rating and price target from Goldman Sachs. Community discourse is currently focused on the company's unique production infrastructure and potential for long-term growth, even as share prices experience short-term volatility tied to broader market trends and conference-related profit taking.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp. is trending as investors weigh significant earnings growth and a massive backlog against ongoing concerns regarding production timelines and short-selling volatility. The community remains focused on the company's role as a domestic supplier of critical minerals for the defense sector, with active debate surrounding potential catalysts like upcoming project milestones and institutional positioning.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. (ANNA) is surging as retail investors rally around its low-float status and strategic role in the European energy sector, with community discussion heavily focused on a potential short squeeze fueled by massive volume and geopolitical supply chain risks. Traders are actively debating the sustainability of this momentum, contrasting bullish sentiment driven by natural gas supply shortages against concerns over volatility and the potential for rapid retracement.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors monitor the commercial launch of YARTEMLEA and weigh upcoming catalysts, including European regulatory milestones and potential milestone payments from the Novo Nordisk partnership. While the community is actively debating the company's valuation and the speed of revenue ramp-up, sentiment remains focused on long-term potential despite recent volatility and discussions around short interest.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending as the community closely monitors the competitive dynamics following a rival's recent FDA approval and anticipates significant clinical data presentations at the upcoming ASH meeting. Investors are heavily focused on potential buyout interest from Incyte, emphasizing the stock's perceived undervaluation and strong pipeline synergy as key drivers for long-term growth.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is currently trending as investors weigh an aggressive $20 billion stock buyback and dividend increase against significant bearish sentiment from analyst downgrades. Community discussion centers on concerns over smartphone market saturation, the long-term impact of losing Apple modem revenue, and intense competition, while bulls point to the company's expansion into automotive and edge AI as key catalysts for long-term growth.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently trending as investors debate the stock's valuation and technical support levels amid intense market volatility surrounding potential tariff impacts on the semiconductor sector. The community is actively discussing the stock's long-term growth prospects in AI and data centers versus its near-term price pressure, with many focusing on whether current levels represent a deep-value buying opportunity or a signal for further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The workforce reduction will be “substantially completed” by Feb. 13.&nbsp;</li><li>As part of the workforce reduction efforts, the company expects to incur a one-time charge of $4.1 million in the first quarter.</li><li>CFO Timothy W. Trost and chief medical officer (CMO) Randi Isaacs will resign as part of the move.</li></ul>Werewolf Therapeutics, Inc. (HOWL) has decided to reduce its workforce by 64% as it seeks to lower its operating costs, the company said in a filing with the Securities and Exchange Commission on Friday.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001785530/000119312526051455/d110809d8k.htm">said</a> that the decision was approved by its Board of Directors on Feb. 9, and the workforce reduction will be “substantially completed” by Feb. 13.As part of the workforce reduction efforts, the company expects to incur a one-time charge of $4.1 million in the first quarter. The amount includes employee separation benefits, including severance and related benefits.Shares of the company rose over 4% after hours after closing down 1% in the regular trading session.<h2 class="st-heading-2">CFO &amp; CMO Exits</h2>CFO Timothy W. Trost and chief medical officer (CMO) Randi Isaacs will resign as part of the move and are entitled to severance benefits including an amount equal to nine months of their base salary, Werewolf Therapeutics said. &nbsp;However, both the executives will assist in aiding a transition of their responsibilities from time to time for up to six months. &nbsp;The company also said on Friday that it is evaluating alternatives such as strategic partnerships for further development of its WTX-124 and WTX-330 INDUKINE programs. It sought to raise capital in the fourth quarter of 2025 as well as the first quarter of 2026 to fund operations and has engaged in investor discussions regarding pipeline and financing, it added.However, the company said on Friday that there is no guarantee that any transaction would occur.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around HOWL stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<a href="https://stocktwits.com/symbol/HOWL">HOWL stock</a> has dropped 57% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/disc-medicine-stock-slumps-after-fda-declines-approval-for-inherited-disorder-drug/cZRd2YMR4tK">Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Werewolf Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Werewolf Therapeutics Stock Rises Over 5% After Hours On Workforce Reduction, Including Executives

The company said that the decision to layoff 64% of its workforce was approved by its board of directions on Feb. 9. 

Equity

The company said that the decision to layoff 64% of its workforce was approved by its board of directions on Feb. 9. 


Luke Evnin Sells 38,782 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 38,782 shares of the company's stock in a transaction on Friday, January 16th. The shares were sold at an average...

Luke Evnin Sells 30,616 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 30,616 shares of the company's stock in a transaction dated Wednesday, January 14th. The stock was sold at an...

Luke Evnin Sells 58,980 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 58,980 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of...

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $11,761.92 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 18,378 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of...

Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 18,568 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 18,568 shares of the business's stock in a transaction on Friday, January 2nd. The shares were sold at an average...

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $22,448.16 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 35,632 shares of the company's stock in a transaction dated Friday, December 26th. The stock was sold at an...

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 17,858 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 17,858 shares of the company's stock in a transaction dated Friday, December 12th. The shares were sold at an...

Luke Evnin Sells 37,104 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock in a transaction on Wednesday, December 10th. The stock was sold at...

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

HOWL
Werewolf Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HOWL News

HOWLWerewolf Therapeutics Inc